Statins: Protectors or pretenders in prostate cancer?

Trends in Endocrinology and Metabolism

Volumn 25, Issue 4, 2014, Pages 188-196

  Moon, Hyeongsun ^a   Hill, Michelle M ^a   Roberts, Matthew J ^a,b,c   Gardiner, Robert A ^b,c   Brown, Andrew J ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Androgen synthesis; Cholesterol; HMG CoA reductase; Prenylation; Prostate cancer; Statin

Indexed keywords

ANDROSTANOLONE; ATORVASTATIN; C REACTIVE PROTEIN; CELECOXIB; CHOLESTEROL; DUTASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN SYNTHESIS; ANTIINFLAMMATORY ACTIVITY; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CHOLESTEROL SYNTHESIS; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOREGULATION; META ANALYSIS (TOPIC); NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SECONDARY PREVENTION; STEROIDOGENESIS; BLOOD; MALE; METABOLISM; PROSTATIC NEOPLASMS;

CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897073920     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.12.007     Document Type: Review

References (82)

1. Siegel R., et al. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Cookson M.S., et al. Castration-resistant prostate cancer: AUA Guideline. J. Urol. 2013, 190:429-438.
3. National Center for Health Statistics Health, United States, 2012 2013, US Department of Health and Human Services.
4. Baigent C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
5. Carey K.M., et al. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann. Pharmacother. 2012, 46:688-695.
6. Bansal D., et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 2012, 7:e46691.
7. Center M.M., et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61:1079-1092.
8. Granieri M.A., Freedland S.J. The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer. BJU Int. 2013, 112:E272.
9. Parker A.S., et al. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013, 16:352-356.
10. Geybels M.S., et al. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013, 73:1214-1222.
11. Freedland S.J., et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2013, 16:254-259.
12. Murtola T.J., et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int. J. Cancer 2010, 127:1650-1659.
13. Loeb S., et al. Is statin use associated with prostate cancer aggressiveness?. BJU Int. 2010, 105:1222-1225.
14. Ku J.H., et al. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis. 2011, 14:63-68.
15. Papadopoulos G., et al. Statins and prostate cancer: molecular and clinical aspects. Eur. J. Cancer 2011, 47:819-830.
16. Hamilton R.J., et al. The influence of statin medications on prostate-specific antigen levels. J. Natl. Cancer Inst. 2008, 100:1511-1518.
17. Chan J.M., et al. Statin use and risk of prostate cancer in the prospective osteoporotic fractures in men (MrOS) study. Cancer Epidemiol. Biomarkers Prev. 2012, 21:1886-1888.
18. Vinogradova Y., et al. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011, 11:409.
19. Breau R.H., et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J. Urol. 2010, 184:494-499.
20. Lustman A., et al. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis. 2013, 10.1038/pcan.2013.34.
21. Auprich M., et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int. 2012, 109:1627-1635.
22. Schröder F.H., et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360:1320-1328.
23. Kollmeier M.A., et al. improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79:713-718.
24. Gutt R., et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol. 2010, 28:2653-2659.
25. Park H.S., et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann. Oncol. 2013, 24:1427-1434.
26. He Z., et al. Cell Killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells. J. Radiat. Res. 2012, 53:225-233.
27. Rieken M., et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2013, 16:367-371.
28. Novara G., et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur. Urol. 2012, 62:382-404.
29. Chao C., et al. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int. 2013, 111:954-962.
30. Chao C., et al. Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett. 2013, 335:214-218.
31. Ritch C.R., et al. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int. 2011, 108:E211-E216.
32. Andriole G.L., et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010, 362:1192-1202.
33. Lehman D.M., et al. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012, 35:1002-1007.
34. Zheng X., et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev. Res. (Phila.) 2010, 3:114-124.
35. Wang C., et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur. Urol. 2010, 58:418-426.
36. Zhuang L., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 2005, 115:959-968.
37. Yokomizo A., et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 2011, 71:298-304.
38. Bjorkhem-Bergman L., et al. What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. Br. J. Clin. Pharmacol. 2011, 72:164-165.
39. Murtola T.J., et al. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL. Eur. J. Pharmacol. 2011, 673:96-100.
40. Roy M., et al. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am. J. Cancer Res. 2011, 1:542-561.
41. Cho K.J., et al. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol. Cell. Biol. 2011, 31:1110-1120.
42. Lewis K.A., et al. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk. Res. 2005, 29:527-533.
43. Solomon K.R., Freeman M.R. Do the cholesterol-lowering properties of statins affect cancer risk?. Trends Endocrinol. Metab. 2008, 19:113-121.
44. Mondul A.M., et al. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011, 22:1545-1552.
45. Pelton K., et al. Cholesterol and prostate cancer. Curr. Opin. Pharmacol. 2012, 12:751-759.
46. Simons K., Sampaio J.L. Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol. 2011, 3:a004697.
47. Oh H.Y., et al. Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochem. Biophys. Res. Commun. 2010, 393:319-324.
48. Llaverias G., et al. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am. J. Pathol. 2010, 177:3180-3191.
49. Fang L., et al. Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 2013, 498:118-122.
50. Tahir S.A., et al. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol. Ther. 2009, 8:2286-2296.
51. Balakumar P., et al. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. J. Mol. Cell. Cardiol. 2012, 52:83-92.
52. Solomon K.R., et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am. J. Pathol. 2009, 174:1017-1026.
53. Basch E., et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013, 14:1193-1199.
54. Ryan C.J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013, 368:138-148.
55. Locke J.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415.
56. Chang K.H., et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013, 154:1074-1084.
57. Mostaghel E.A., et al. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 2012, 7:e30062.
58. Martinez-Martos J.M., et al. Diet-induced hypercholesterolemia impaired testicular steroidogenesis in mice through the renin-angiotensin system. Gen. Comp. Endocrinol. 2011, 173:15-19.
59. Seo Y.K., et al. Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. Exp. Cell Res. 2009, 315:3133-3139.
60. Banez L.L., et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 2010, 19:722-728.
61. Ridker P.M., et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352:20-28.
62. Spann N.J., Glass C.K. Sterols and oxysterols in immune cell function. Nat. Immunol. 2013, 14:893-900.
63. Last A.R., et al. Pharmacologic treatment of hyperlipidemia. Am. Fam. Physician 2011, 84:551-558.
64. Krycer J.R., Brown A.J. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim. Biophys. Acta 2013, 1835:219-229.
65. Sadowitz B., et al. Basic science review section: statin therapy. Part II: clinical considerations for cardiovascular disease. Vasc. Endovascular Surg. 2010, 44:421-433.
66. Sirtori C.R., et al. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann. Med. 2012, 44:419-432.
67. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin. Drug Saf. 2011, 10:373-387.
68. Eckel R.H. Approach to the patient who is intolerant of statin therapy. J. Clin. Endocrinol. Metab. 2010, 95:2015-2022.
69. Nassar Z.D., et al. Caveola-forming proteins caveolin-1 and PTRF in prostate cancer. Nat. Rev. Urol. 2013, 10:529-536.
70. Thompson T.C., et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010, 13:6-11.
71. Moon H., et al. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene 2013, 10.1038/onc.2013.315.
72. Giannoni E., et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
73. Tahir S.A., et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008, 68:731-739.
74. Bist A., et al. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:10693-10698.
75. Schooling C.M., et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013, 11:57.
76. Schnoeller T., et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J. Urol. 2013, 31:253-259.
77. Khera M., et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur. Urol. 2014, 65:115-123.
78. Allott E.H., et al. Obesity and prostate cancer: weighing the evidence. Eur. Urol. 2013, 63:800-809.
79. Wang C., et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011, 34:1669-1675.
80. Brown A.J. Cholesterol, statins and cancer. Clin. Exp. Pharmacol. Physiol. 2007, 34:135-141.
81. Wong J., et al. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2365-2371.
82. Saylor P.J., Smith M.R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 2013, 189:S34-S42.